This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutIntroducing Enbrel®Heritage of Enbrel®IndicationsTherapeutic IndicationsRheumatoid ArthritisJuvenile Idiopathic ArthritisPsoriatic ArthritisAxial SpondyloarthritisPsoriasis & Paediatric PsoriasisMechanism of actionMode of ActionHalf-lifeDosingDosingRheumatoid Arthritis, Psoriatic Arthritis & Axial SpondyloarthritisJuvenile Idiopathic ArthritisPsoriasisPaediatric PsoriasisAdministration & StorageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacyRapid EffectivenessSustained EffectivenessEffectiveness With Monotherapy or Combination TherapySafetyTolerability Across IndicationsSummary of Prescribing InformationImmunogenicityImmunogenicity & Clinical ResponseImmunogenicity & Enbrel®Experience & InsightsExperience & InsightManufacturingPatient StoriesRheumatoid ArthritisPatient With an Increased Risk of Serious InfectionsMTX-IR PatientPatient Who Is Considering Starting a FamilyElderly-onset RA PatientYoung Patient Worried About the Lifelong Impact of RAYoung Patient Worried About Treatments That Lose Effectiveness Over TimeJuvenile Idiopathic ArthritisJuvenile PatientPatient Moving From Childhood to AdolescenceAxial SpondyloarthritisAS Patients With Heel EnthesitisAS Patients With Functional LimitationsAdvanced AS PatientsPsoriatic Arthritis & PsoriasisPsO Patient With Severe SymptomsPsO Patients With Cyclical SymptomsPsA Patient With Metabolic SyndromePsA Patient With Multiple Skin & Joint SymptomsSupport & ServicesSupport & ServicesUsing Enbrel®Summary of Prescribing InformationPatient ResourcesEventsMaterialsVideos

Patient With an Increased Risk of Serious Infections

Meet Neha, a 42-year-old RA patient1 who has an increased risk of serious infections due to multiple factors.2-4

     

Elderly-onset RA Patient

‘I was shocked when my doctor told me that I have RA – especially when I learned that my disease activity is considered high.3

    

‘I’ve always been generally healthy, although I am a smoker2 and was recently hospitalised for pneumonia.4

    

‘I’ve heard that some treatments for RA can increase the risk of infections– and that scares me a lot’.

    

~2× increased risk of serious bacterial infections with TNFi treatment.5,*

   

Note: This is a hypothetical case for representation purpose only.

‘I’ve always been generally healthy, although I am a smoker and was recently hospitalised for pneumonia’.

      

Patients such as Neha benefit from a lower risk of serious infections with Enbrel®6,7

  • Significantly lower adjusted risk of serious infections in RA versus both adalimumab and infliximab6,†
     
    • Unadjusted risk was also lower with Enbrel® versus both adalimumab and infliximab6
       
  • Lower risks of serious infections, discontinuations due to AEs and tuberculosis than both adalimumab and infliximab7,‡

From the DREAM biological registry, which included 2356 patients with RA followed up to 5 years.6,†

    

Unadjusted Incidence Rate of a First Serious Infection6

    

    

Adapted from van Dartel SA, et al. 2013.

    

    

Please consult the LPD for contraindications, warnings, precautions and other important safety information.

    

    

Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.

    

*From a retrospective study that compared 2393 patients with RA who received TNFi versus 2933 patients with RA who received MTX. Compared with patients who received MTX alone: adjHR = 1.9 (95% CI, 1.3-2.8).5

     

Among 2356 patients with RA followed up to 5 years in the DREAM biological registry.6

    

Study design: van Dartel SA, et al. 2013.

    

The objective of this study was to analyse whether the risk of serious infections in patients with RA starting TNF-inhibiting therapy is different for adalimumab, infliximab and Enbrel®, in a head-to-head comparison with a follow-up time of up to 5 years. Data were extracted from the DREAM biological registry (since 2003) and a preceding biological registry from the RUNMC (before 2003), both with the same inclusion criteria and work flow. Incidence rates were calculated from the observed number of first serious infections for a follow-up time of up to 5 years. A Cox proportional hazards model with time-to-first-serious infection was used to estimate risk differences among the TNFi treatment groups, with correction for confounders.6

    

Serious infections in patients treated with Enbrel® versus adalimumab: adjHR = 0.55 (95% CI, 0.44-0.67); Enbrel® versus infliximab: adjHR = 0.49 (95% CI, 0.29-0.83).6

    

Results of a systematic review of 10 randomised trials and 51 observational studies that evaluated a total of >100,000 patients.
The majority of evaluated trials/studies (70%) was conducted in patients with RA.7

    

adjHR, adjusted hazard ratio; AE, adverse event; CI, confidence interval; DREAM, Dutch RhEumatoid Arthritis Monitoring; MTX, methotrexate; RA, rheumatoid arthritis; RUNMC, Radboud University Nijmegen Medical Centre; SmPC, summary of product characteristics; TNF, tumour necrosis factor; TNFi, tumour necrosis factor inhibitor.

    

References:

Enbrel. Local product document. Version LPDENB062021.Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61.Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785-791.Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914-1920.Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125-1133.van Dartel SA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895-900.Desai RJ, Thaler KJ, Mahlknecht P, et al. Comparative risk of harm associated with the use of targeted immunomodulators: A systematic review. Arthritis Care Res (Hoboken). 2016;68(8):1078-1088.

    

Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

    

PP-ENB-IND-0814 August 2022

    

From the DREAM biological registry, which included 2356 patients with RA followed up to 5 years.5,†

    

From the DREAM biological registry, which included 2356 patients with RA followed up to 5 years.5,†

Rheumatoid Arthritis
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ENB-IND-0814

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​